

Tables

1.1	Public pharmaceutical expenditure as a percentage of public health expenditure	4
1.2	Cost sharing in the health systems of western European countries	8
1.3	Pharmaceutical expenditure as a percentage of total health expenditure	12
3.1	Main forms of price regulation in EU countries in 1997	40
3.2	Criteria used in the price regulation of pharmaceuticals in the OECD	42
4.1	Retail sales of pharmaceutical products	62
4.2	Therapeutic classifications	64
4.3	Number of active ingredients, pharmaceutical products and pharmaceutical presentations	65
4.4	Therapeutic competition in the pharmaceutical market as a whole (%)	66
4.5	Therapeutic competition: number of active ingredients	67
4.6	Therapeutic competition: market share of the most prescribed active ingredient (%)	68
4.7	Therapeutic competition: <i>H</i> index of prescription concentration between various therapeutic substances (%)	69
4.8	Generic competition (%)	71
4.9	Length of time substances have been on the market (%)	72
4.10	Generic competition: number of products per active ingredient	73
4.11	Generic competition: market share of the most prescribed product (%)	75
4.12	Generic competition: <i>H</i> index of product prescription concentration (%)	77
4.13	Prescription of different preparations per product	78
4.14	Average price per item prescribed in the public health sector	81
4.15	Number of items prescribed per patient	82
5.1	Factors affecting price competition on the supply side and the demand side	91
5.2	Comparison of the results of the hypothetical application of a single price or Ramsey prices in a two-country model	95

6.1	Evolution of public health expenditure in Spain (1989–2001) (%)	104
6.2	National expenditure on health care and pharmaceuticals in Europe (1997)	107
6.3	Some international experiences in the application of RP	109
6.4	The kinked demand model	111
7.1	Effects of cost sharing on financing, use and equity	128
8.1	Costs and benefits of social programmes	153
8.2	Costs and benefits of non-dominated alternatives	154
8.3	Ordering of programmes according to incremental cost–benefit ratios	155
8.4	Probabilities and utilities of each regulatory policy	159
8.5	Example of a utility function	164
9.1	Measures aimed at influencing prescription	170
9.2	Measures aimed at influencing prescription as applied in some EU countries	172
9.3	Prescriber incentive policies	175
10.1	Distribution by categories of the 50 top-selling drugs in the world, years: 1988–2002 (estimate) (number of products)	193
10.2	Weighted average price of pharmaceuticals in the main EU countries in 2001 (Spain 100)	194
10.3	Spanish Social Security drug consumption through pharmacies (retail price plus VAT) (1988–2001)	195
10.4	Public pharmaceutical expenditure as a percentage of GDP	196
10.5	Public pharmaceutical expenditure as a percentage of total public health expenditure	196
10.6	Some other (financing) pharmaceutical indicators, 2000	197
10.7	Total drug consumption in the EU in euros per person per year, 2000	198
10.8	Pharmaceutical consumption and expenditure in Spanish Social Security prescriptions per insured person per year (1995–2001) in pesetas/year	198
10.9	Average sum per prescription of pharmaceutical products in the Spanish Social Security market (retail price plus VAT) 1992–2001	199
10.10	Pharmaceutical expenditure in Europe by categories in 1999 (in million US\$)	199
10.11	Some cost-containment measures in the pharmaceutical sector	202